Close menu




March 12th, 2021 | 07:25 CET

CureVac, Pollux Properties, SAP - Go for the latecomers!

  • Investments
Photo credits: pixabay.com

At the moment, a shift from technology stocks to value stocks is taking place on the global stock markets. Companies that outperformed after bottoming out in March 2020 are losing disproportionately in the current market phase. In contrast, many investors are currently betting on the supposed re-opening winners such as TUI and Lufthansa & Co. Here, several stocks have enormous catch-up potential and are lagging behind in their performance.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , SG1I77884290 , DE0007164600

Table of contents:


    Corona dents everywhere

    Germany was not the only country to feel the force of the economic downturn. Even Asia, which is admittedly coping better with the pandemic, had to let up in certain sectors. In Singapore, the city-state with the highest standard of living in the Southeast Asian region, the average economic growth in recent years was 13% per year. In the Corona year 2020, however, Singapore's economy shrank by 5.8%, according to estimates by the Ministry of Trade and Industry. The commercial real estate market was also hit hard. Here, the price index for office space fell by 10.73%. Private real estate, on the other hand, increased in price by 2.2%. Office rents are expected to drop by around 5% in 2021 due to the expansion of home office spaces and savings measures in rents.

    With a tailwind into the future

    Singapore's stock returns were also among the weakest in Asia in 2020. However, with the start of global Covid-19 vaccinations, Singapore fund managers expect returns to rise sharply again this year and economic growth to continue ahead of Corona. Despite the Corona Crisis year, Pollux Properties is well-positioned due to its three-legged portfolio. The Company manages properties worth the equivalent of around EUR 200 million in Singapore, with an extensive portfolio of residential properties and office and retail space. Although the real estate development segment came to a standstill in 2020, the Company maintained its sales at around the previous year's level despite Corona thanks to its existing properties and its third pillar, fund management.

    Favorable opportunity

    The payment of a dividend was waived for 2020. Due to the expected upswing that experts expect for property prices in Singapore in the next few years, we expect dividend payments to increase continuously in the coming years. As of the end of December 2020, the Company had a cash balance of EUR 19.74 million. The portfolio real estate segment is to be strongly expanded. Likewise, the Company is still in the early stages of fund management. Here, the Company is aiming for a significantly higher fund volume. In the long term, Pollux Properties offers an interesting entry opportunity. The stock market value is currently EUR 66.6 million. In addition to the domestic market in Singapore, the shares are also traded in Germany.

    Before admission

    Compared to other countries, Germany is only progressing at a snail's pace with its vaccination program. Currently, only 3% of the population has been vaccinated twice. In addition to BioNTech, Moderna and the criticized AstraZeneca vaccine, Johnson & Johnson's vaccine is expected to be added this week, which should speed up the vaccination process once again. The EU has ordered 200 million units from Johnson & Johnson, with 55 million expected to be ready by the end of June. Next in line should be the second German manufacturer, CureVac AG. The rolling approval procedure was applied for 3 weeks ago. The submission of the data relates to the preclinical and Phase 1 data, which are already with the regulatory authority EMA.

    According to the Company's management, good progress is being made in terms of safety and tolerability. The CureVac vaccine should also be effective against mutations. The Tübingen share reached a high of EUR 125 in December, then entered a consolidation phase. Currently, the breakout area at EUR 70 was tested, which has already been held several times. Due to further positive news flow, the share is striving for the annual high of EUR 110. The stock is currently attractive as a trading position.

    When will the gap close?

    After the third quarter's disappointing figures, the price gap at around EUR 125 still needs to be closed for the software provider SAP. The Walldorf-based Company is currently trading at EUR 105, around EUR 5 below the breakout level. While SAP was still struggling with the weakened cloud business last year, the competition made extremely successful progress in this business. Oracle, for example, reported strong quarterly figures due to its strong cloud business with IT applications and storage space on the Internet. At the bottom line, the Group earned EUR 5.0 billion, EUR 4.2 billion in the three months to the end of February, almost twice as much as a year ago.

    The figures for SAP subsidiary Qualtrics were also strong. It significantly reduced its loss in the fourth quarter. Subscription revenue rose by a third to USD 160.4 million in the quarter. The Nasdaq-listed subsidiary posted a net loss of USD 14.5 million, or USD 0.03 per share, in the final quarter, compared with a loss of USD 147.3 million, or USD 0.35 per share, in the same period the previous year. Analysts were expecting significantly lower earnings.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read